Book excerpt: Many anti-viral vaccines elicit neutralizing antibodies as a correlate of protection. For HIV-1, given the enormous variability of the virus, it is widely believed that the induction of a broadly neutralizing antibody (bNAb) response will be crucial in a successful vaccine against the virus. There are, however, major challenges in the development of immunogens that elicit bNAbs. Our strategy toward the rational design of an HIV-1 vaccine involves characterizing the epitopes of bNAbs and designing immunogens to re-elicit these types of antibodies.